Because of the risk of liver damage with JUXTAPID, the Food and Drug Administration (FDA) has required a special program called a Risk Evaluation and Mitigation Strategy (REMS).
As part of REMS your prescriber will discuss the risks of JUXTAPID with you, and review the Patient Guide to the REMS.
After reviewing the JUXTAPID REMS information, both you and your healthcare provider will be asked to complete a form acknowledging that you understand the risks with the use of JUXTAPID.